These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 18808404)

  • 21. Rituximab as induction therapy after renal transplantation: a randomized, double-blind, placebo-controlled study of efficacy and safety.
    van den Hoogen MW; Kamburova EG; Baas MC; Steenbergen EJ; Florquin S; M Koenen HJ; Joosten I; Hilbrands LB
    Am J Transplant; 2015 Feb; 15(2):407-16. PubMed ID: 25612493
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Multicenter trial exploring calcineurin inhibitors avoidance in renal transplantation.
    Vincenti F; Ramos E; Brattstrom C; Cho S; Ekberg H; Grinyo J; Johnson R; Kuypers D; Stuart F; Khanna A; Navarro M; Nashan B
    Transplantation; 2001 May; 71(9):1282-7. PubMed ID: 11397963
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Rituximab in immunologic glomerular diseases.
    Ejaz AA; Asmar A; Alsabbagh MM; Ahsan N
    MAbs; 2012; 4(2):198-207. PubMed ID: 22377738
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Successful treatment of chronic antibody-mediated rejection with IVIG and rituximab in pediatric renal transplant recipients.
    Billing H; Rieger S; Ovens J; Süsal C; Melk A; Waldherr R; Opelz G; Tönshoff B
    Transplantation; 2008 Nov; 86(9):1214-21. PubMed ID: 19005402
    [TBL] [Abstract][Full Text] [Related]  

  • 25. ABO-incompatible live donor renal transplantation using blood group A/B carbohydrate antigen immunoadsorption and anti-CD20 antibody treatment.
    Nordén G; Briggs D; Cockwell P; Lipkin G; Mjörnstedt L; Mölne J; Ready A; Rydberg L; Samuelsson O; Svalander CT; Breimer ME
    Xenotransplantation; 2006 Mar; 13(2):148-53. PubMed ID: 16623810
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Proteasome inhibitor-based primary therapy for antibody-mediated renal allograft rejection.
    Walsh RC; Everly JJ; Brailey P; Rike AH; Arend LJ; Mogilishetty G; Govil A; Roy-Chaudhury P; Alloway RR; Woodle ES
    Transplantation; 2010 Feb; 89(3):277-84. PubMed ID: 20145517
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Rituximab and intravenous immunoglobulin treatment of chronic antibody-mediated kidney allograft rejection.
    Fehr T; Rüsi B; Fischer A; Hopfer H; Wüthrich RP; Gaspert A
    Transplantation; 2009 Jun; 87(12):1837-41. PubMed ID: 19543061
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Rationale and design of the RIACT-study: a multi-center placebo controlled double blind study to test the efficacy of RItuximab in Acute Cellular tubulointerstitial rejection with B-cell infiltrates in renal Transplant patients: study protocol for a randomized controlled trial.
    Schiffer L; Schiffer M; Merkel S; Schwarz A; Mengel M; Jürgens C; Schroeder C; Zoerner AA; Püllmann K; Bröcker V; Becker JU; Dämmrich ME; Träder J; Grosshennig A; Biertz F; Haller H; Koch A; Gwinner W
    Trials; 2012 Oct; 13():199. PubMed ID: 23101480
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Living donor kidney transplantation in patients with donor-specific HLA antibodies enabled by anti-CD20 therapy and peritransplant apheresis.
    Klein K; Süsal C; Schäfer SM; Becker LE; Beimler J; Schwenger V; Zeier M; Schemmer P; Macher-Goeppinger S; Scherer S; Opelz G; Morath C
    Atheroscler Suppl; 2013 Jan; 14(1):199-202. PubMed ID: 23357165
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effect of steroid-free low concentration calcineurin inhibitor maintenance immunosuppression regimen on renal allograft histopathology and function.
    Nainani N; Patel N; Tahir N; Kumar R; Weber-Shrikant E; Gundroo AA; Murray BM; Tornatore KM; Blessios GA; Venuto RC
    Nephrol Dial Transplant; 2012 May; 27(5):2077-83. PubMed ID: 22058172
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Rituximab therapy for acute humoral rejection after kidney transplantation.
    Faguer S; Kamar N; Guilbeaud-Frugier C; Fort M; Modesto A; Mari A; Ribes D; Cointault O; Lavayssière L; Guitard J; Durand D; Rostaing L
    Transplantation; 2007 May; 83(9):1277-80. PubMed ID: 17496547
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The utility of 6-month protocol renal biopsy under modern immunosuppression.
    Yango A; Gohh R; Wang LJ; Morrissey P; Shih M; Lowery K; Charpentier K; Gautam A; Mendonca C; Kumar S; Dworkin L; Monaco A
    Clin Nephrol; 2008 Dec; 70(6):490-5. PubMed ID: 19049705
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Rituximab removes intrarenal B cell clusters in patients with renal vascular allograft rejection.
    Steinmetz OM; Lange-Hüsken F; Turner JE; Vernauer A; Helmchen U; Stahl RA; Thaiss F; Panzer U
    Transplantation; 2007 Oct; 84(7):842-50. PubMed ID: 17984836
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Acute kidney graft rejection. A morphological and immunohistological study on "zero-hour" and follow-up biopsies with special emphasis on cellular infiltrates and adhesion molecules.
    Andersen CB; Ladefoged SD; Larsen S
    APMIS; 1994 Jan; 102(1):23-37. PubMed ID: 7513171
    [TBL] [Abstract][Full Text] [Related]  

  • 35. B cells in cluster or in a scattered pattern do not correlate with clinical outcome of renal allograft rejection.
    Scheepstra C; Bemelman FJ; van der Loos C; Rowshani AT; van Donselaar-Van der Pant KA; Idu MM; ten Berge IJ; Florquin S
    Transplantation; 2008 Sep; 86(6):772-8. PubMed ID: 18813100
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Antibody-mediated rejection and treatment in pediatric patients: one center's experience.
    Gulleroglu K; Baskin E; Bayrakci US; Turan M; Ozdemir BH; Moray G; Karakayali H; Haberal M
    Exp Clin Transplant; 2013 Oct; 11(5):404-7. PubMed ID: 24128133
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Crossmatch-positive liver transplantation in patients receiving thymoglobulin-rituximab induction.
    Kubal CA; Mangus RS; Saxena R; Lobashevsky A; Higgins N; Agarwal A; Fridell JA; Tector AJ
    Transplantation; 2014 Jan; 97(1):56-63. PubMed ID: 24030603
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Expression patterns of B cells in acute kidney transplant rejection.
    Carpio VN; Noronha Ide L; Martins HL; Jobim LF; Gil BC; Külzer AS; Loreto Mda S; Gonçalves LF; Manfro RC; Veronese FV
    Exp Clin Transplant; 2014 Oct; 12(5):405-14. PubMed ID: 25299368
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Development of antibody mediated rejection shortly after acute cellular rejection in a pediatric kidney transplantation recipient.
    Okada M; Kamei K; Matsuoka K; Ito S
    CEN Case Rep; 2018 Nov; 7(2):288-291. PubMed ID: 29949115
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Impact of rituximab therapy on response to tetanus toxoid vaccination in kidney-transplant patients.
    Puissant-Lubrano B; Rostaing L; Kamar N; Abbal M; Fort M; Blancher A
    Exp Clin Transplant; 2010 Mar; 8(1):19-28. PubMed ID: 20199367
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.